FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 331 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... March 21, 2019 Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer April 27, 2018 FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities December 1, 2020 Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer... February 4, 2020 Load more HOT NEWS ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... Suzanne Somers Discusses Her Cancer Diagnosis And Thinking Of Her ‘Mortality’ A Daily Survival Kit for Serious Illness EMA Recommends Granting a Marketing Authorisation for Capivasertib
